Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087373 · ClinicalTrials.gov registry record · Phase 2
Vaccine Therapy in Treating Patients With Metastatic Melanoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 28
- Enrollment target
NCT00087373: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00087373 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 28 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087373, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 28 participants
- Enrollment target
Study Summary
Vaccines may make the body build an immune response to kill tumor cells. Injecting a vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells. This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.
Interventions
- OTHER laboratory biomarker analysis
- BIOLOGICAL recombinant fowlpox-TRICOM vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2004-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087373
The ClinicalTrials.gov registry entry for NCT00087373 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00087373 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087373 about?
NCT00087373 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Melanoma". Vaccines may make the body build an immune response to kill tumor cells. Injecting a vaccine directly into a tumor may cause a stronger immune response and kill more tumor cells. This phase II trial is studying how well vaccine therapy works in treating patients with metastatic melanoma.
What is the current status of trial NCT00087373?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 28 participants. The study started on 2004-06.
What interventions are being tested in trial NCT00087373?
The interventions under investigation include: laboratory biomarker analysis (OTHER), recombinant fowlpox-TRICOM vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT00087373?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.